This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindström, S. Articles by Grönberg, H. Search for Related Content PubMed PubMed Citation Articles by Lindström, S. Articles by Grönberg, H.

Germ-Line Genetic Variation in the Key Androgen-Regulating Genes Androgen Receptor, Cytochrome P450, and Steroid-5--Reductase Type 2 Is Important for Prostate Cancer Development

¹ Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden and ² Department of Medical Epidemiology and Biostatistics and ³ Oncologic Center, CLINTEC, Karolinska Institutet, Stockholm, Sweden

Requests for reprints: Sara Lindström, Department of Radiation Sciences, Oncology, Umeå University, SE-901 85 Umeå, Sweden. Phone: 46-90-785-47-34; Fax: 46-90-12-74-64; E-mail: sara.lindstrom{at}oc.umu.se.

Prostate cancer risk may be influenced by single genetic variants in the hormone-regulating genes androgen receptor (AR), cytochrome P450 (CYP17), and steroid-5--reductase type 2 (SRD5A2). In this study, we comprehensively investigated polymorphisms in these three loci and their joint effect in a large population-based study. We selected 23 haplotype-tagging single-nucleotide polymorphisms (htSNP) that could uniquely describe >95% of the haplotypes (6 in AR, 6 in CYP17, and 11 in SRD5A2). These htSNPs were then genotyped in the Cancer Prostate in Sweden population (2,826 case subjects and 1,705 controls). We observed significant association for several SNPs in the AR gene (P = 0.004-0.02) and CYP17 (P = 0.009-0.05) and one SNP in SRD5A2 (P = 0.02). Carriers of the most common AR haplotype had a significant excess risk to develop prostate cancer [odds ratio (OR), 1.25; 95% confidence interval (95% CI), 1.1-1.5; P = 0.002], yielding an estimated population attributable risk of 16% (95% CI, 0.06-0.25). Combining risk alleles from these genes yielded a 12% risk increase for each additional high-risk allele carried (95% CI, 1.1-1.2; P for trend = 9.2 x 10^–5), with an overall OR of 1.87 (95% CI, 1.0-3.4) for carriers of all five included risk alleles, an OR of 2.13 (P for trend = 8 x 10^–4) for advanced disease, and an OR of 4.35 (P for trend = 7 x 10^–5) for disease onset before age 65 years. Genetic variation in key genes in the androgen pathway is important for development of prostate cancer and may account for a considerable proportion of all prostate cancers. Carriers of five high-risk alleles in the AR, CYP17, and SRD5A2 genes are at 2-fold excess risk to develop prostate cancer. (Cancer Res 2006; 66(22): 11077-83)

This article has been cited by other articles:

				J. Li, R. J. Coates, M. Gwinn, and M. J. Khoury Steroid 5-{alpha}-Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review Am. J. Epidemiol., November 13, 2009; (2009) kwp318v1. [Abstract] [Full Text] [PDF]

				S. Lindstrom, H.-O. Adami, J. Adolfsson, and F. Wiklund Y Chromosome Haplotypes and Prostate Cancer in Sweden Clin. Cancer Res., October 15, 2008; 14(20): 6712 - 6716. [Abstract] [Full Text] [PDF]

				S. L. Zheng, J. Sun, F. Wiklund, S. Smith, P. Stattin, G. Li, H.-O. Adami, F.-C. Hsu, Y. Zhu, K. Balter, et al. Cumulative Association of Five Genetic Variants with Prostate Cancer N. Engl. J. Med., February 28, 2008; 358(9): 910 - 919. [Abstract] [Full Text] [PDF]

				M. A. Albertelli, O. A. O'Mahony, M. Brogley, J. Tosoian, M. Steinkamp, S. Daignault, K. Wojno, and D. M. Robins Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice Hum. Mol. Genet., January 1, 2008; 17(1): 98 - 110. [Abstract] [Full Text] [PDF]

				V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al. CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246. [Abstract] [Full Text] [PDF]

				S. L. Zheng, J. Sun, Y. Cheng, G. Li, F.-C. Hsu, Y. Zhu, B.-L. Chang, W. Liu, J. W. Kim, A. R. Turner, et al. Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans J Natl Cancer Inst, October 17, 2007; 99(20): 1525 - 1533. [Abstract] [Full Text] [PDF]

				S. Lindstrom, H.-O. Adami, K. A. Balter, J. Xu, S. L. Zheng, P. Stattin, H. Gronberg, and F. Wiklund Inherited Variation in Hormone-Regulating Genes and Prostate Cancer Survival Clin. Cancer Res., September 1, 2007; 13(17): 5156 - 5161. [Abstract] [Full Text] [PDF]